Isabelle Fenner
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- COVID-19 Clinical Research Studies 10
- Clostridium difficile and Clostridium perfringens research 1
- Surgery 1
- Kawasaki Disease and Coronary Complications 1
- Co-authors
- Martin Holfelder (1 shared paper)Ulrich Eigner (1 shared paper)Klaus Oberdorfer (1 shared paper)
- Journals
- The Lancet (6 papers)Nature Communications (1 paper)EClinicalMedicine (1 paper)The Lancet Infectious Diseases (1 paper)The Lancet Diabetes & Endocrinology (1 paper)
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Isabelle Fenner
12 papers receiving 1.6k citations
Isabelle Fenner's Hit Papers
Peers
Comparison fields: 5 of 82
- Infectious Diseases 1.3k
- Applied Microbiology and Biotechnology 35
- Internal Medicine 27
- Statistics and Probability 47
- Oncology 75
Countries citing papers authored by Isabelle Fenner
This map shows the geographic impact of Isabelle Fenner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Fenner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Fenner more than expected).
Fields of papers citing papers by Isabelle Fenner
This network shows the impact of papers produced by Isabelle Fenner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Fenner. The network helps show where Isabelle Fenner may publish in the future.
Co-authors
The 3 scholars most cited alongside Isabelle Fenner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 7 | 2023 | 25 | |
| 8 | 2024 | 24 | |
| 9 | 2024 | 6 | |
| 10 | 2014 | 5 | |
| 11 | 2025 | 5 | |
| 12 | 2025 | 2 |
About Isabelle Fenner
Isabelle Fenner is a scholar working on Infectious Diseases, Surgery, Nuclear Energy and Engineering, Waste Management and Disposal and Organic Chemistry, having authored 12 papers that have together received 1.7k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (10 papers), Kawasaki Disease and Coronary Complications (1 paper) and Clostridium difficile and Clostridium perfringens research (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (27 citations), Statistics and Probability (47 citations) and Oncology (75 citations). Isabelle Fenner has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Frequent co-authors include Martin Holfelder, Ulrich Eigner and Klaus Oberdorfer. Their work appears in journals such as The Lancet, Nature Communications, EClinicalMedicine, The Lancet Infectious Diseases and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.